Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.44 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19764100 | 1.00 | LMNA (0.55) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL10423427 | 0.88 | CHRNB2 (0.50) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL9335217 | 0.88 | LMNA (0.45) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL19267535 | 0.85 | CHRNB2 (0.52) | LMNAKMT2AKDM4EGAANPC1 | |
| SCHEMBL17563257 | 0.84 | CHRNB2 (0.41) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL12121752 | 0.84 | PRPS1 (0.44) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL30089764 | 0.84 | CHRNB2 (0.41) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL13137241 | 0.84 | CHRNB2 (0.41) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL22704837 | 0.84 | DYRK1A (0.46) | LMNAMEN1KMT2APOLBKDM4E | |
| SCHEMBL19915916 | 0.82 | LMNA (0.55) | LMNAMEN1KMT2APOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430738-A | Catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| US-7169948-B2 | Anionic and neutral complexes of ruthenium (II) with nitrogen oxide | SIGEA S.R.L. (IT) | 2007-01-30 | — | — | US | claimed |
| EP-1392707-B1 | NEW ANIONIC AND NEUTRAL COMPLEXES OF RUTHENIUM (II) WITH NITROGEN OXIDE | SIGEA SRL (IT) | 2005-11-09 | — | — | EP | claimed |
| US-20040106799-A1 | Anionic and neutral complexes of ruthenium (II) with nitrogen oxide | SIGEA S.R.L. (IT) | 2004-06-03 | — | — | US | claimed |
| EP-1228077-B1 | RUTHENIUM (II) COMPLEXES WITH HIGH ANTITUMORAL AND ANTIMETASTATIC ACTIVITIES | SIGEA SRL (IT) | 2003-06-11 | — | — | EP | claimed |
| EP-0915895-B1 | NEW SALTS OF ANIONIC COMPLEXES OF RU(III), AS ANTIMETASTATIC AND ANTINEOPLASTIC AGENTS | SIGEA SRL (IT) | 2003-05-21 | — | — | EP | claimed |
| US-6221905-B1 | ANTICANCER AGENTS | SIGEA S.R.L. (IT) | 2001-04-24 | — | — | US | claimed |
| CN-115974788-B | Method for synthesizing alpha-straight-chain alkyl substituted heteroarene | 苏州大学 | 2025-06-17 | — | — | CN | disclosed |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024077391-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIVERSITE DE MONTREAL (CA) | 2024-04-18 | — | — | WO | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024026596-A1 | METHOD FOR SYNTHESIZING α-LINEAR ALKYL SUBSTITUTED HETEROARENE | 苏州大学 | 2024-02-08 | — | — | WO | disclosed |
| CN-117430738-A | Catalyst component for olefin polymerization, catalyst and application thereof | 中国石油化工股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-0709375-A2 | Therapeutic heterocycles | ZENECA LIMITED (GB) | 1996-05-01 | — | — | EP | disclosed |
| US-5015473-A | Beta-lactamase inhibitors | PFIZER INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-4898872-A | Imidazo[4,5-b]pyridyl quinolone cardiac stimulants | PFIZER INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4826833-A | ANTIBIOTICS | PFIZER INC. (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0290153-A1 | Heterobicyclic quinolone derivatives | Pfizer Limited (GB) | 1988-11-09 | — | — | EP | disclosed |
| US-4595701-A | Reacting carbon monoxide and hydrogen in liquid phase in the presence of a rhodium and trialkylphosphine catalyst | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1986-06-17 | — | — | US | disclosed |
| US-4460709-A | Process for producing oxygen-containing organic compounds | AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) | 1984-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | LMNA 1542/4885MEN1 4692/4885KMT2A 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.